目的： 用Meta分析的方法定量评价干扰素辅助治疗肝癌的效果。 方法： 计算机检索EMbase、PubMed、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库(CNKI)、维普中文科技期刊数据库，收集有关干扰素辅助治疗肝癌的随机对照试验（randomized controlled trial，RCT），两名评价者单独评价纳入研究的方法学质量并提取资料，用Cochrane协作网提供的RevMan5.0软件进行Meta分析。 结果： 共纳入8篇RCTs，共计836例患者。Meta分析结果显示，肝癌患者接受基础治疗后，干扰素辅助治疗组在复发率方面与安慰剂组相比，差异有统计学意义\[RR=0.86，95%CI（0.77，0.96），P<0.05\]；两组在病死率方面的差异也有统计学意义\[RR=0.64，95%CI（0.54,0.76），P<0.05\]。 结论： 干扰素辅助治疗可以降低肝癌患者的病死率和复发率，但远期疗效尚待大样本、高质量的RCTs进一步证实。

Objective : To quantitatively assess the efficacy of interferon (IFN) in the adjuvant treatment for patients with hepatocellular carcinoma (HCC) using Meta analysis. Methods: Randomized controlled trials (RCTs) of adjuvant treatment with interferon for patients with HCC were searched in Embase, Medline, Cochrane Library, Chinese biomedicine literature database, Chinese Scientific Journals full-text database, and Chinese Journal full-text databases. Two reviewers independently assessed the quality of included studies and extracted data. Meta analysis was carried out using Review Manager (version 5.0) provided by Cochrane Collaboration. Results: Eight RCTs totaling 836 patients were included. Meta analysis showed that the adjuvant treatment with IFN significantly reduced the recurrence rate after curative treatment of HCC, with a pooled risk ratio of 0.86 (95 percent confidence interval 0.77 to 0.96); the effect on reduction in mortality rate was still significant with a pooled risk ratio of 0.64 (95 percent confidence interval 0.54 to 0.76). Conclusion: IFN has a beneficial effect on both mortality rate and tumour recurrence, and the results still need to be confirmed by RCTs of high quality and large sample size.